Home
About Us
Membership
Member Biography

Member Biography

Sherif S. Farag, MD, PhD

Sherif S. Farag, M.D., Ph.D.

Phone: (317) 278-0460
Phone: (317) 944-0920, Patient issues/appointments

980 W. Walnut St.
R3 312
Indianapolis, IN 46202

Faculty appointments

Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Kenneth Wiseman Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, IU School of Medicine
Adjunct Professor of Medical & Molecular Genetics, Department of Medical and Molecular Genetics, IU School of Medicine
Full member, Experimental and Developmental Therapeutics

a) Development novel approaches to hematopoietic stem cell transplantation, including safer approaches to alternate donor transplantation through depletion of alloreactive T cells, utilization of KIR mismatches between donor and recipient, harnessing Treg cells, and NKT cells. b) Development of novel agents and regimens for the treatment of multiple myeloma. This includes pre-clinical research of novel agents (drug development).

A Randomized, Double-Blind, Placebo-Controlled Multicenter Phase III Trial of Alpha 1 - Antitrypsin (AAT) Combined with Corticosteroids vs Corticosteroids Alone for the Treatment of High Risk Acute Graft-versus-Host Disease (GVHD) Following Allogeneic Hematopoietic Stem Cell TransplantCTO-BMTCTN1705

Intermediate-Size Population Expanded Access Program (EAP) for cilta-cel Out‐of‐Specification (OOS) in Patients with Multiple MyelomaECRO-JANSSEN-EAP-MMY4006

Phase I/II Trial of High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell TransplantationCTO-IUSCCC-0778

Reduced Intensity Conditioning for Haploidentical Bone Marrow Transplantation in Patients with Symptomatic Sickle Cell DiseaseBMTCTN1507

Composite Health Assessment Risk Model for Older Adults: Applying Pre-transplant Comorbidity, Geriatric Assessment, and Biomarkers to Predict Non-Relapse Mortality after Allogeneic Transplant (CHARM)CTO-BMTCTN1704

Indiana University Simon Cancer Center Hematologic Malignancies Tissue BankIUCRO-0216

BMT CTN 1703/1801: A Randomized, Multi-Center, Phase III Trial of Tacrolimus/ Methotrexate versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (PROGRESS III)/Companion Study: Microbiome and Immune Reconstitution in Cellular Therapies and Hematopoietic Stem Cell Transplantation (Mi-Immune)BMTCTN1703/1801

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (CTRLALT-D)BMTCTN1702

Expanded Access Protocol (EAP) for Subjects Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial ReleaseECRO-CELGENE-BB2121-EAP-001

Headlines & highlights

IU cancer center findings could reduce treatment-related complication for blood cancer patients (Jan. 2021)

#ResearchCuresCancer

Support Our Research